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Abstract The molecular mechanism of herpes simplex virus
(HSV) entry and the associated inflammatory response in the
nervous system remain poorly understood. Using mouse-
derived ex vivo dorsal root ganglia (DRG) explant model
and single cell neurons (SCNs), in this study, we provided a
visual evidence for the expression of heparan sulfate (HS) and
3-O-sulfated heparan sulfate (3-OS HS) followed by their in-
teractions with HSV-1 glycoprotein B (gB) and glycoprotein
D (gD) during cell entry. Upon heparanase treatment of DRG-
derived SCN, a significant inhibition of HSV-1 entry was
observed suggesting the involvement of HS role during viral
entry. Finally, a cytokine array profile generated duringHSV-1
infection in DRG explant indicated an enhanced expression of
chemokines (LIX, TIMP-2, and M-CSF)—known regulators
of HS. Taken together, these results highlight the significance
of HS during HSV-1 entry in DRG explant. Further investiga-
tion is needed to understand which isoforms of 3-O-
sulfotransferase (3-OST)-generated HS contributed during
HSV-1 infection and associated cell damage.
Keywords HSVentry . Heparan sulfate . Sensory neurons .
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Introduction
The hallmark of herpes simplex virus type 1 (HSV-1) infection is
to establish life-long latency in the sensory ganglia mainly in the
dorsal root ganglia (DRG) of the host following an initial infec-
tion in epithelial cells (Roizman and Whitley 2013; Fraser and
Valyi-Nagy 1993; Wilson and Mohr 2012). Upon reactivation,
the virus resumes its cycle of lytic gene expression to replicate
successfully and transport newly made virions axonally back
either to peripheral nervous system, resulting in cold sores or
fever blisters and corneal keratitis, or central nervous system
resulting in meningitis and encephalitis in the brain (Whitley
and Roizman 2001; Nicoll et al. 2012; Simmons 2002).
The process of HSV-1 entry initiates with the specific in-
teraction between viral envelope glycoproteins and host cell
surface receptors (Antoine et al. 2013; Spear 2004; Hadigal
and Shukla 2013; Connolly et al. 2011). The HSV glycopro-
teins B and C (gB and gC, respectively) mediate their initial
attachment to host cell surface heparan sulfate proteoglycans
(HSPG) (Shukla and Spear 2001; Tiwari et al. 2015; WuDunn
and Spear 1989; Herold et al. 1991; Shieh et al. 1992). The
initial binding step of the virus to HSPG results in a confor-
mational change that brings major viral glycoprotein D (gD)
binding domain to interact with any given host cell receptors
(nectin, HVEM, and 3-O-sulfated heparan sulfate; 3-OS HS).
The later process involves three additional HSV glycopro-
teins, gB, gH, and gL, and possibly an additional gH co-re-
ceptor, which trigger the fusion of the viral envelope with the
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plasma membrane of host cells (Geraghty et al. 1998;
Montgomery et al. 1996; Shukla et al. 1999; Eisenberg et al.
2012).
Interestingly, recent studies widely documented the role of
heparan sulfate (HS) and the HS-degrading enzyme
heparanase in the pathological process including neuroinflam-
mation (Zhang et al. 2014; Li and Vlodavsky 2009; Parish
2006; Hadigal et al. 2015). Therefore, understanding the in-
volvement of HS and modified HS in HSV-1 entry, spread,
and cell damage at the molecular level will aid in the devel-
opment of novel strategies to prevent virus spread and associ-
ated inflammation (Joyce et al. 2005; Rusnati et al. 2005;
Ferro et al. 2007; Tiwari et al. 2011; Raman et al. 2012). In
this study, we investigated the interaction between HSV-1
glycoproteins and HS (Yabe and Maeda 2015) and modified
3-OS HS generated by the enzyme 3-O-sulfotransferase (3-
OST) (Yabe et al. 2005).
In order to achieve our goal, we developed a mouse-
derived ex vivo DRG explant and single cell neuronal
(SCN) cultures as a model to study HSV-1 entry. We observed
the susceptibility and replication of KOS HSV-1 strain in the
DRG explants. In addition, our data further provided the vi-
sual and quantitative evidence to support the significance of
HS, 3-OS HS, in promoting HSVentry and inducing changes
in the pattern of expression of unique sub-set of chemokines.
Finally, we propose that DRG-based ex vivo model provides a
unique platform to further investigate which form of HS is
critical for viral entry and cell damage.
Material and methods
An overall experimental design is schematically described in
the Fig. 1.
Harvesting of DRG In accordance with institutional review
board-approved protocols (IACUC—Midwestern
University), mouse-derived DRG explants were isolated from
adult NIH/Swiss mice (Harlan Laboratories, Chicago, IL).
Briefly, the animals were euthanized and the vertebral column
was surgically dissected. The vertebral canal was exposed by
performing a double cut on both sides of the vertebral bodies
using fine scissors. The ventral access through the vertebral
bodies did not interfere with the DRG located along the dorsal
roots. DRGs were localized on both sides of the spinal cord,
removed, and cleaned from excess of fibers and connective
tissue. DRG explants were then plated ex vivo in 12-well
plates pre-coated with matrigel (Sigma-Aldrich, St. Louis,
MO) in serum-free medium (SFM) (Fueshko and Wray
1994) and maintained in culture conditions (37 °C and 5%
CO2) for up to 6 days. The medium was changed every 72 h.
Generating single cell neurons fromDRGsAfter collection,
explants were immediately placed in F12 media (Gibco,
Waltham, MA) containing collagenase (1.25 mg/ml) (Sigma-
Aldrich, St. Louis, MO) and incubated (37 °C and 5% CO2)
for 45 min. The collagenase step was repeated for another
45 min. Afterward, explants were incubated in F12 media
containing trypsin (0.025%, Sigma-Aldrich, St. Louis, MO)
mixture for 30 min followed by F12 media-containing FBS
(Sigma-Aldrich, St. Louis, MO) for 15 min. Thereafter, ex-
plants were washed three times with F12 media and mechan-
ically dissociated with a glass pipette until the solution turned
cloudy indicating a successful dissociation. Dissociated cells
were filtered through a 0.22-μm filter (BD Falcon, Franklin
Lakes, NJ) and centrifuged (2400 rpm) for 2 min. After re-
moving the supernatant, the cells were resuspended in
neurobasal media (Sigma-Aldrich, St. Louis, MO) containing
B-27 supplement (Life Technologies, Carlsbad, CA), PSN
antibiotics (Gibco, Waltham, MA), 0.5 mM L-glutamine
(Sigma-Aldrich, St. Louis, MO) and NGF (5 ng/ml,
Alomone Labs, Jerusalem, Israel). The resuspended cells were
plated on laminin-coated cover slides (Neuvitro, Vancouver,
WA).
HSV-1 infection in DRG explants
Groups of three DRG explants/tubes were infected with HSV-
1 gL86 (10,000 virions) in serum-free media. After 12 h of
infection at 37 °C, explants were washed with PBS, fixed, and
permeabilized, using buffer followed by incubation with X-
Gal (5-bromo-4-chloro-3-indolyl-β-D-galactosidase;
Invitrogen) at 1.0 mg/ml, which yields an insoluble blue-
stained product upon hydrolysis by β-galactosidase. Blue
cells (representing viral entry) were seen at multiple locations
per explant as shown in the supplementary figures (Fig. 1S).
Microscopy was performed using Zeiss Axiovert 100.
Plaque formation using infected DRGs
A group of three DRG explants per well in triplicate experi-
ment was cultured for 3 days prior to be infected with
replication-competent syn mutant HSV-1(KOS-804) (Little
and Schaffer 1981) or mock infected with PBS alone as a
control for 2 h at 37 °C (Fig. 2S). After removal of the un-
bound virus, DRG explants were overlaid with SFM and in-
cubated at 37 °C until the time of harvest of inoculums (12, 24,
and 36 h). Inoculum of DRG explants infected with HSV-1 or
mock treated was laid on Vero cells cultured in triplicate to
visualize plaque formation. In order to block secondary plaque
formation, human immunoglobulin G (IgG; 1:10 Sigma-
Aldrich, St. Louis, MO) was added to the inoculums. The
Vero cells were washed with PBS buffer, fixed in ethanol
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80%, and stained withGiemsa stain. Infectivity was quantified
by counting the number of plaques.
Immunofluorescence assay
DRG explants and SCNs were either uninfected or infected
with HSV-1 (KOS-804) at a concentration of 1.0 multiplicity
of infection (MOI) for SCNs and 10,000 virions for explants.
Samples were incubated for 1 and 12 h in neurobasal media
under 5% CO2 at 37 °C. After infection, they were fixed with
4% formaldehyde (Sigma-Aldrich, St. Louis, MO) for 1 h and
washed with PBS three times for 15 min each. Explants were
embedded in 3% agarose and sectioned at a thickness of
100 μm using a vibratome (Pelco 100). Both sections and
SCNs were incubated in primary antibodies overnight at
4 °C. The following antibodies were used: anti-gD (Abcam,
1:10); anti-gB (Thermo Scientific, 1:1000); anti-TrkC
(Abcam, 1:1000); anti-HS (US Biological, 1:200); anti-3-
OST-2 (Santa Cruz, 1:500); and Phage display derived anti-
body HS4C3, reactive with 3-OS HS (Ten Dam et al. 2006),
1:10. Primary antibodies were diluted in PBS (0.3% Triton X,
0.1% sodium azide) and 1% normal serum (Vector laborato-
ries; Burlingame, CA). The next day, DRG explants and SCNs
were washed with PBS 3× for 15 min and incubated with
secondary antibodies for 1 h for all conditions except the ones
labeled with anti-3-OS HS HS4C3 antibody (Ten Dam et al.
2006), which were incubated for 2 h in secondary antibody
(anti-VSV), in the dark at room temperature. The secondary
antibodies used were Alexa Fluor 488 goat anti-mouse IgG
(Life Technologies, Canada) at 1:500 dilution, Cy3-
AffiniPure goat anti-rabbit IgG (H+L) (Li StarFish, Italy) at
1:500 dilution, donkey anti-rabbit (Invitrogen, Rockford, IL)
at 1:400 dilution, donkey anti-goat (Invitrogen, Rockford, IL)
at 1:400 dilution, and mouse monoclonal IgG to VSV-GVSV
(P5D4, Santa Cruz, Dallas, TX) at 1:200 dilution. All other
conditions that did not include anti-3-OS HS were washed
with PBS 3× for 15 min. Samples labeled with anti-3-OS
HS (HS4C3) antibody were further incubated with goat anti-
mouse Alexa Fluor 488. The samples were finally mounted on
a microscope slide using Vectashield Hard Set™ Mounting
Medium with DAPI (Vector laboratories, Burlingame, CA).
Samples were imaged using the Nikon Eclipse Ti A1R
confocal microscope and analyzed using the NIS-Elements
software.
Heparanase assay
SCNs were pre-treated with heparanase I and II (Sigma-
Aldrich, St. Louis, MO) at 1 unit/ml for 3 h at 37 °C with
5% CO2 (Tiwari et al. 2004). After pre-treatment of SCNs
with heparanase and or mock treatment, the SCNs were in-
fected with HSV-1 gL86 at 1 MOI for 2 h in neurobasal media
Fig. 1 Schematic representation of the experimental procedures carried
out in this study. DRGs were isolated from adult NIH/Swiss mice and
either plated ex vivo as a whole explant or dissociated into single cell
cultures composed of neurons and satellite cells. These two models were
infected with HSV-1 KOS (gL86) reporter virus for the β-galactosidase
and heparinase/ONPG assay. HSV-1 (KOS-804) replication competent
virus was used for plaque formation and inflammatory antibody array
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at 37 °C with 5% CO2. The cells were then washed to remove
any unbound viruses and were let to incubate in fresh
neurobasal media overnight at 37 °C with 5% CO2 followed
by the addition of ortho-nitrophenyl-β-D-galactopyranoside
(ONPG) substrate (Pierce, Rockford, IL). The β-
galactosidase activity was measured at 410 nm wavelength
using the microplate reader (PerkinElmer EnSpire: multimode
plate reader).
Cytokine assay
Using a RayBio cytokine antibody array (RayBio, Norcross,
GA), we assessed the expression of inflammatory markers
during HSV-1 infection in mouse-derived DRG explants
ex vivo (Baldwin et al. 2013). We used HSV-1 (KOS) 804
virus strain at a low concentration (10,000 virions) to infect
DRG. DRGs mock infected with PBS were used as control.
The supernatant of treated explants was collected after 12, 24,
and 36 h post-infection. The cytokine antibody array was per-
formed in accordance with the manufacturer’s instructions as
previously described (Baldwin et al. 2013). The expression of
each cytokine was evaluated in triplicate, quantified, and nor-
malized as per manufacturer’s instructions (Fig. 4S).
Results
Susceptibility of mouse-derived DRG to HSV infectionWe
first isolated DRGs from adult NIH/Swiss mice and
established an ex vivo model to study HSV-1 infection. A
group of three DRG explants plated per well in triplicate ex-
periment was challenged in a dosage-dependent manner with
reporter β-galactosidase expressing HSV-1 KOS (gL86) vi-
rions at 37 °C or mock infected using the same culture condi-
tions at various time points. Viral entry assay was quantified
based on the amount of β-galactosidase expressed from the
viral genome in whichβ-galactosidase expression is inducible
by HSV infection (data not shown). Next, we determined
HSV-1 replication by visualizing viral plaque assay
(Fig. 2S). DRG explants were infected with replication-
competent HSV-1 (KOS-804) strain (10,000 virions) or
mock-infected explants at 37 °C for 24 h. To visualize plaque
formation, Vero cells were overlaid with either the infected or
the mock-infected DRG’s inoculum for 12, 24, and 36 h. The
results show a larger number of plaques in a time-dependent
manner. In contrast, no plaque was noticed in mock-infected
DRGs (Fig. 2S).
Altogether, these results indicate the susceptibility of
mouse-derived DRG ex vivo explants to HSV-1 infection.
Expression of HS and localization of HSV-1 gB with HS in
HSV-1-infected DRGs and SCNs We next investigated the
initial stages of HSV-1 infection in DRG and SCN models.
Our focus was on HS, a widely recognized receptor involved
in mediating HSV-1 attachment or binding at the host cell
surface (Herold et al. 1991; Shieh et al. 1992). First, we con-
firmed the expression of HS in high-resolution confocal mi-
croscopy on both whole DRG tissue sections and DRG-
derived SCN models (Fig. 2a, b). Immunofluorescence con-
focal microscopy confirmed an evenly distributed expression
of HS (anti-HS antibody 10E4 epitope, US Biological) among
the neuronal population in the whole DRG tissue section
(Fig. 2a). Similarly, a wide expression of HS was also ob-
served in DRG-derived SCN (Fig. 2b). The isolation of pri-
mary single cell DRG neurons does not account for purifica-
tion of just neuronal cells. A sub-population of satellite cells is
still present. Therefore, we used neuronal specific marker
TrkC to confirm the neuronal phenotype of the cell population
used for this study (Fig. 2a, b).
After confirming HS expression in both models, we then
infected DRGs (10,000 virions) and SCNs (1.0 MOI), with
HSV-1 (KOS) 804 virus for 1 h at 37 °C to visualize HSV-1
binding or attachment. As shown in Fig. 2c, d, a co-
localization between HSV-1 gB and HS was clearly observed
at the surface of the neuronal cell bodies in both models indi-
cating the initial participation of HS in the event of viral
attachment.
Co-localization between HSV-1 gD and 3-OS HS in both
DRGs and SCNs We next evaluated if DRGs and SCNs
express the modified version of HS which is 3-O-sulfated
heparan sulfate (3-OS HS). The latter form of HS is a product
of enzymatic modification by 3-O-sulfotransferase (3-OSTs)
(Esko and Lindahl 2001). Previous studies have shown that 3-
OS HS, generated by 3-OST-3 isoforms, allows HSV-1 entry
by interacting to HSV-1 glycoprotein D (Shukla et al. 1999).
The presence of 3-OST-2 enzyme was confirmed in our neu-
ronal models by immunofluorescence (Supplementary
Fig. 3S). As indicated in Fig. 3a, b, a punctate labeling for -
3-OS HS was observed on the cell surface of TrkC-positive
neurons. This result provided the rationale to further examine
the interaction between HSV-1 glycoprotein D (gD) and 3-OS
HS, a step essential for virus-cell fusion (Shukla et al. 1999;
Tiwari et al. 2004, 2007). These experiments were conducted
using whole DRGs and SCNs infected with HSV-1 or mock
infected for either 1 (Fig. 3c, d) or 12 h (Fig. 3e, f), respec-
tively. Samples were fixed and immunolabeled with anti-
HSV-1 gD and anti-3-OS HS (HS4C3) antibodies. As shown
in Fig. 3c, d, HSV-1 gD-3-OS HS yellow co-localization at
1-h post-infection (p.i.) was observed at the surface of DRGs
and SCNs, respectively. Interestingly, at later time point (12 h,
p.i.), a similar yellow co-localization was observed in the mid-
section of the sliced cells in both of the models (DRGs:
Fig. 3e, and SCNs: Fig. 3f). The later results suggest the role
of 3-OS HS receptor in HSV-1 trafficking.
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Enzymatic removal of cell surface HS significantly reduces
HSV-1 entry in SCNs To assess whether HS and 3-OS HS
play a crucial role in virus entry, SCNs were pre-treated with
enzymes heparanase I and II (1 U/ml). This enzyme selective-
ly cleaves both heparin and HS chains containing 1 → 4
linkages between glucosamines and O-sulfated iduronic acid
residues (Ernst et al. 1995). Mock-treated SCNs were used as
control. Thereafter, SCNs were infected with β-galactosidase
expressing HSV-1 gL86 reporter virions (1 MOI) for 2 h at
37 °C and 5% CO2. Quantification of HSV Lac Z expression
showed a significant (P = 0.0036) decrease of viral entry in the
heparanase treated SCNs (0.1691 ± 0.006) compared tomock-
treated (0.2053 ± 0.002) control (Fig. 4). The previous results
suggest a possible role for HS and 3-OS HS in HSV-1 entry in
our single neuron model.
Cytokine array analysis during HSV-1 infection in DRG
explant Cytokines are a very heterogeneous family of mole-
cules involved in inflammatory responses (Cavaillon and
Haeffner-Cavaillon 1993; Newton and Dixit 2012;
Mogensen 2009). Therefore, we sought to determine if DRG
explants could produce inflammatory response to HSV-1 in-
fection. A panel of more than 40 cytokines was tested in
triplicate experiment in DRG explants infected with HSV-1
(KOS-804, 10,000 virions) at 12, 24, and 36 h p.i. Mock-
infected DRGs were used as a control. The results of the entire
panel are shown in the supplementary Fig. 4S. Interestingly,
HSV-1 notably affected the expression of many members of
the cytokine family at different time points. For instance, a
quantitative analysis revealed a significant decrease in expres-
sion of interferon (IFN)-γ, RANTES, and TNF-α at 12 h p.i.
On the contrary, other two members of the family, LIX and
TIMP-2, significantly increase at 24 h. A similar result is seen
for M-CSF at 36 h (Fig. 5).
Discussion
In this study, we developed mouse-derived DRG explants and
SCN models to investigate early stages of HSV-1 infectivity.
Using confocal microscopy, we first demonstrated that diverse
chains of HS (HS and 3-OS HS) are present on the surface of
DRGs and SCNs as evident from the results of the immuno-
fluorescence experiments (Figs. 2 and 3). The variability in
the HS chain has been associated with the generation of bind-
ing sites for specific ligands and therefore plays a critical role
Fig. 2 Expression and localization of heparan sulfate (HS) in dorsal root
ganglia (DRG) and single cell neurons (SCN). Sections of DRGs (a) and
SCNs (b) were double labeled using the anti-HS 10E4 epitope FITC-
conjugated antibody and the specific neuronal marker against TrkC
receptor showing that HS is widely expressed on the surface of DRG
neurons. Samples were mounted on coverslips with mounting medium
containing blue DAPI, which labels the nucleus. HSV-1-infected DRGs
and SCNs (c, d) were then double labeled with anti-glycoprotein B (gB,
red) and anti-HSmarker (green). As control, a section of uninfected DRG
double labeled with anti-gB and anti-HS antibodies is shown in c, inset.
Confocal imaging displayed sequestration and accumulation of HS
(yellow) in the membrane region. Scale bars: a–d = 25 μm (color
figure online)
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in maintaining and performing multiple biological functions
including neuronal growth (Esko and Lindahl 2001;
Mogensen and Paludan 2001; Thacker et al. 2016; Bishop
et al. 2007). On the other hand, multiple pathogens including
herpes viruses exploit variability in HS chain in their benefit
by facilitating pathogenesis (Tiwari et al. 2012; O’Donnell
and Shukla 2008). Our result established the first step of
HSV-1 attachment/binding by demonstrating the co-
localization between glycoprotein B (gB) to HS (Fig. 2). In
addition, we also provided evidence of virus-cell fusion by co-
localization between HSV-1 gD and 3-OS HS (Fig. 3). We
further tested if HS and 3-OS HSwere critical for HSV-1 entry
in our model systems. Upon enzymatic treatment with
heparanase I and II, which selectively cleaves sulfated resi-
dues in HS, a significant reduction in HSV infection was no-
ticed in the DRG-derived SCNs suggesting the significance
for HS/3-OS HS in mediating virus infection (Fig. 4).
Finally, to gain more detail insight to the post-infection
inflammatory response in DRGmodel, a previously described
chemokine array analysis was performed (Baldwin et al.
2013). We noticed significant increase (LIX, TIMP-2, and
M-CSF) and decrease (IFN-γ, RANTES, and TNF-α) in spe-
cific chemokines, which are interestingly known to influence
inflammatory response either by binding directly to HS and
sulfated HS or by affecting HS-dependent or HS-independent
signaling pathways (Lortat-Jacob et al. 2002; Lortat-Jacob
Fig. 3 Expression and localization of 3-O-sulfated heparan sulfate (3-OS
HS) in dorsal root ganglia (DRG) and single cell neurons (SCN). Sections
of DRGs (a) and SCNs (b) were double labeled for anti-3-OS HS sulfate
using the anti-HS (HS4C3) FITC-conjugated antibody and the specific
neuronal marker against TrkC receptor (red) showing that 3-OS HS
sulfate is widely expressed on the surfaces of the neuronal bodies.
Samples were mounted on coverslips with mounting medium
containing the nuclear stain blue DAPI. Both DRG tissue sections and
SCNs were then infected with HSV-1 for either 1 (c, d) or 12 h (e, f),
respectively. Double immunofluorescence with specific antibody for both
HSV-1 glycoprotein gD (red) and 3-OS HS sulfate (green) revealed co-
localization (yellow, arrow) of the two markers more in the neuronal cell
surface at 1 h time point (c, d). In contrast, at 12 h, the co-localization of
the two markers (arrows) is seen more internally, in the proximity of the
nuclear region (e, f). The images were taken in confocal microscopy.
Scale bars: a–f = 25 μm (color figure online)
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2009; Davis and Parish 2013; Wang and Knaut 2014). Several
interesting observations were generated from our chemokine
array analysis. For instance, we noticed an enhanced expres-
sion of neurospecific TIMP-2 in HSV-1-infected cell.
Interestingly, an upregulation of TIMP-2 has been linked to
FGF/EGF signaling that controls cell proliferation, differenti-
ation, neurite growth (Fager and Jaworski 2000; Young et al.
2002), and markers for the ECM accumulation and fibrosis
(Jaworski and Pérez-Martínez 2006; Arpino et al. 2015). The
increase observed forM-CSF in our model of HSV-1 infection
correlates with data previously obtained in P19 neuronal-like
cells infected with HSV-1 (Smith et al. 2013; Dixit et al.
2008). In that case, as well as for other models, an enhance-
ment of M-CSF in the brain was linked to cytoskeleton reor-
ganization, phagocytosis, and several disease processes in-
cluding neuroinflammation (Smith et al. 2013; Dixit et al.
2008). In addition, our previous finding showed a novel
phagocytic uptake of HSV-1 as a primary mechanism in cor-
neal fibroblasts derived from human eye donors (Clement
et al. 2006). Further investigation will determine if M-CSF
plays a major role in phagocytic uptake of HSV-1.
Similarly, an enhanced signal for LIX (CXCL5) was ob-
served in HSV-1-infected DRG explants compared to mock
infected (Fig. 5). LIX is a well-known marker for neuroin-
flammation, and it has been reported to be upregulated in
response via a phosphatidylinositol 3-kinase (PI3 kinase)
and NF-kappa B pathway. As previously reported, PI3 kinase
signaling affects multiple steps during HSVentry (Tiwari and
Shukla 2010).
Fig. 5 Inflammatory signals in DRG explant upon HSV-1 infection. A
RayBio cytokine antibody array (RayBio, Norcross, GA) as per the
manufacturer’s instructions was used to assess inflammatory markers
produced in HSV-1 (KOS) 804 (10,000 virions) infection of ex vivo
DRG explant at 12, 24, and 36 h. The experiment was run in triplicates.
Signal intensities of various inflammatory markers are plotted in
uninfected (grey bars) versus HSV-1 infected DRGs (black bars) at
different time points. Inflammatory markers that resulted in significant
decrease (IFN-γ (P = 0.027), RANTES (P = 0.011), and TNF-α
(P = 0.038)) and increase (LIX (P = 0.032), TIMP-2 (P = 0.013), and
M-CSF (P = 0.011)) in their signal intensities compared to their
uninfected controls are indicated
Fig. 4 Enzymatic removal of cell surface HS results significant
inhibition in HSV-1 entry in DRG-derived SCNs. SCNs were treated
with heparanase I and II (1 U/ml; H+) or mock treated with 1× PBS (H−
for 3 h at 37 °C. SCNs were then challenged with β-galactosidase
expressing reporter HSV-1 gL86 virus (1 MOI). After 12 h, cells were
permeabilized and incubated with ONPG substrate for quantitation of β-
galactosidase activity expressed from the input viral genome. Enzymatic
activity was measured (H+ sample: 0.1691 ± 0.006; H− sample:
0.2053 ± 0.002) by determining OD410. Data represent the mean ± the
standard deviation of results in triplicate wells in a representative
experiment. The experiment was repeated three times with similar results
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Finally, a significant reduction of RANTES (CCL5),
TNF-α, and IFN-γ was observed during early phase of
HSV-1 infection (Fig. 5). Interestingly, RANTES is a key
player in enhancing viral binding or attachment by cross-
linking virus and cell, a process that involves chemokine-HS
binding (Trkola et al. 1999). The expression of TNF-α and
IFN-γ neuroinflammatory markers increases at 24–36 h
(Fig. 4S) post-HSV-1 infection (Olmos and Lladó 2014).
In summary, with this study, we established ex vivo DRG
explants and DRG-derived SCNs as model systems to study
HSV-1 entry and associated neuroinflammation. Our data
clearly suggest the involvement of HS and 3-OS HS in medi-
ating HSV-1 infection. Further investigations are required to
address which inflammatory cytokine are specifically induced
under which sub-set of sulfated HS (Lawrence et al. 2007).
These findings, together with additional information on the
critical epitopes involved during HSV-1 gD interaction with
3-OSHS, will advance our current understanding on the HSV-
1-induced pathogenesis, neuroinflammation, and tissue dam-
age. The results of these experiments will be extremely useful
for the development of the novel therapeutic interventions.
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